Select Medical Reports Q1 Revenue Increase Despite Margin Pressures
Select Medical Holdings has reported a 5% increase in revenue for the first quarter of 2026, reaching $1.42 billion, slightly surpassing the anticipated figure of $1.41 billion. Despite this revenue growth, GAAP earnings per share were $0.36, 20.6% below analyst expectations of $0.46. The adjusted EBITDA came in at $141.6 million, falling short by 8.6%. The company reaffirmed its full-year revenue guidance of approximately $5.7 billion with a midpoint GAAP EPS of $1.27 and EBITDA of $530 million, aligning with market forecasts.
Operationally, the company saw its operating margin decrease to 6.9% from 8.3% the previous year. Sales volumes improved by 1% compared to a year ago, contributing to a total market capitalization currently standing at $2.04 billion.
The first quarter results underscore Select Medical's growth in revenue across various sectors, although profit margins were impacted. Challenges in the outpatient rehabilitation sector and lower Medicare Advantage conversion rates in the critical illness recovery division affected earnings. CEO Thomas Mullen noted costs associated with strategic market exits, specifically the closure of four clinics in Oregon.
Strategic Developments and Future Outlook
The company's strategic outlook includes developments in inpatient rehabilitation, with plans to add 275 hospital beds via new openings and expansions over the next 18 months. CFO Michael Malatesta expressed confidence in meeting year-end expectations despite margin pressures. Challenges persist with increased Medicare Advantage denials, but leadership sees potential growth from commercial and Medicare patient intake.
On the regulatory side, Select Medical operates in an environment where CMS's proposed payment increases provide stability, although Medicare Advantage denials continue to pose challenges. The company is committed to advocacy efforts to influence future reimbursement models positively.
The Board has approved a take-private transaction led by Executive Chairman Robert Ortenzio, slated for completion by mid-2026. This move will transition the company to private ownership, impacting reporting and financial structuring moving forward.
Select Medical continues to explore outpatient rehabilitation consolidations, closing underperforming clinics to enhance efficiency and margins. The company emphasizes capacity expansion and operational efficiency while navigating payer dynamics in the current healthcare landscape. Trading at $16.45, Select Medical maintains a consistent price point following recent earnings announcements. Stakeholders should monitor the upcoming take-private transaction and ongoing operational initiatives, which could significantly influence future performance and company structure.